DDInter1340 DDInter107
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer .
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anisindione
Anisindione {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Omeprazole {u} (Compound) resembles {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anisindione
Anisindione {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anisindione
Anisindione {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Omeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Barrett's esophagus {u} (Disease) is treated by {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Omeprazole {u} (Compound) resembles {v} (Compound) Rabeprazole
Rabeprazole {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Omeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Omeprazole (Compound) treats Barrett's esophagus (Disease) and Barrett's esophagus (Disease) is treated by Esomeprazole (Compound) and Es
Omeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Omeprazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Omeprazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Omeprazole (Compound) resembles Rabeprazole (Compound) and Rabeprazole may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide